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A B S T R A C T
Following the 2009 H1N1 influenza pandemic, an increased risk of narcolepsy type 1 was observed. Homology
between an H1N1 hemagglutinin and two hypocretin sequences has been reported.
T cell reactivity to these peptides was assessed in 81 narcolepsy type 1 patients and 19 HLA-DQ6-matched
healthy controls.
HLA-DQ6-restricted H1N1 hemagglutinin-specific T cell responses were detected in 28.4% of patients and
15.8% of controls. Despite structural homology between HLA-DQ6-hypocretin and -H1N1 peptide complexes, T
cell cross-reactivity was not detected.
These results indicate that it is unlikely that cross-reactivity between H1N1 hemagglutinin and hypocretin
peptides presented by HLA-DQ6 is involved in the development of narcolepsy.
1. Introduction
Narcolepsy type 1 (NT1) is a rare disorder of the regulation of sleep
and wakefulness with an incidence of 1 per 100,000 person years and a
prevalence ranging between 20 and 50 per 100,000 individuals
(Ohayon et al., 2002; Wijnans et al., 2013). The disorder is char-
acterised by five core symptoms: excessive daytime sleepiness, cata-
plexy, hypnagogic hallucinations, sleep paralysis and disturbed noc-
turnal sleep. These symptoms arise as a result of the destruction of over
90% of hypocretin (Hcrt)-producing neurons in the lateral hypotha-
lamus (Peyron et al., 2000; Thannickal et al., 2000). Unfortunately,
causal treatment of the disorder is not yet available.
In pursuit of the disease mechanism, two findings have shifted the
focus of narcolepsy research to the hypothesis that the destruction of
Hcrt-producing neurons is caused by an auto-immune process. First,
95% of NT1 patients carry the HLA-DQA1*01:02 / DQB1*06:02 hap-
lotype encoding HLA-DQ6, an HLA-class II molecule expressed on an-
tigen-presenting cells (Juji et al., 1984; Mignot et al., 1997; Tafti et al.,
2014), which was later complemented by genome-wide association
studies that showed variants within immune system-regulating genes in
narcolepsy patients (Faraco et al., 2013; Han et al., 2013; Hor et al.,
2010). Second, an increase in the incidence of NT1 has been observed in
several European countries after the 2009 H1N1 influenza pandemic,
and the subsequent vaccination campaign (Dauvilliers et al., 2013;
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Feltelius et al., 2015; Lind et al., 2014; Partinen et al., 2012). Even
though there was no wide-spread vaccination campaign in Asian
countries, an increased incidence has also been reported in China (Han
et al., 2011). This suggests that NT1 might develop as the result of a
cross-reactive anti-viral immune response that leads to the destruction
of Hcrt-producing neurons. More insight in this reaction could pave the
way for causal treatment development in NT1 and potentially also
prevention of the disease by identifying individuals at-risk.
Research on the auto-immune reaction has focused on two candi-
date immune cell types that could drive this reaction leading to NT1:
cross-reactive B cells and cross- or autoreactive CD4+ T cells. Four
studies (Black et al., 2005; Overeem et al., 2006; Tanaka et al., 2006;
Van Der Heide et al., 2015) failed to detect autoreactive B cells or au-
toantibodies to Hcrt or Hcrt-receptors. Another group claimed to have
identified autoreactive CD4+ T cells specific for Hcrt (De La Herran-
Arita et al., 2013; De La Herran-Arita et al., 2014), but the article was
subsequently retracted. While HLA-DR-restricted Hcrt-specific T cell
responses have recently been described (Latorre et al., 2018), this does
not explain the strong link with HLA-DQ6. In short, the molecular
mechanism underlying the HLA-DQ6 association remains to be de-
termined.
Based on the increased incidence of NT1 after the H1N1 influenza
pandemic mentioned above, we aimed to assess whether H1N1 influ-
enza reactive CD4+ T cells are present in NT1 patients. A secondary
aim was to assess whether these H1N1 influenza specific CD4+ T cells
cross-react with Hcrt. We determined the crystal structure of one earlier
identified H1N1 hemagglutinin peptide and two Hcrt peptides bound to
the disease-predisposing HLA-DQ6 molecules to assess structural
homology. Subsequently, we stimulated peripheral blood mononuclear
cells with these peptides to generate specific T cell lines and clones. We
then performed proliferation tests on these clones to assess both H1N1-
and Hcrt-reactivity and assess HLA-DQ6 restriction, cross-reactivity and
T cell receptor sequence of these clones.
2. Materials and methods
2.1. Subjects
Between March 2014 and June 2016, we included all consecutive
narcolepsy type 1 patients after informed consent, recruited from the
sleep clinic of the department of Neurology, Leiden University Medical
Center and the Sleep-Wake Centre of Stichting Epilepsie Instellingen
Nederland (SEIN), Heemstede. All patients were diagnosed with nar-
colepsy type 1 according to the International Classification of Sleep
Disorders (ICSD-3; (American Academy of Sleep Medicine, 2014)).
Symptom onset in all patients was after the 2009 H1N1 pandemic.
Healthy controls were included in the same time period as the narco-
lepsy type 1 patients and matched for HLA and gender.
2.2. Hcrt-1 measurements
CSF samples were drawn for Hcrt-1 measurement in 34 narcolepsy
type 1 patients. Hypocretin-1 concentrations were measured in dupli-
cate with an I125 hypocretin-1 radioimmunoassay (Phoenix
Pharmaceuticals, Mountain View, CA, USA). This assay has an intra-
assay variability of< 5% and a detection limit of 50 pg/mL. To adjust
for inter-assay variability, Stanford reference CSF samples were in-
cluded in the assay (Ripley et al., 2001; Mignot et al., 2002).
2.3. Peptides
All peptides used were produced at the Peptide Synthesis Facility of
the Department of Immunohematology and Blood Transfusions of the
Leiden University Medical Center. Two Hcrt peptides, Hcrt56–68 and
Hcrt87–99, and one 2009 H1N1 influenza A hemagglutinin (H1N1-HA)
peptide, H1N1-HA275–287, were selected based on sequence similarity
between these peptides and those described in the aforementioned re-
tracted article (De La Herran-Arita et al., 2013; De La Herran-Arita
et al., 2014). All peptide sequences can be found in Supplemental
Table 1.
For follow-up experiments, we used processed Hcrt peptides: two
truncated peptides lacking the first 4 residues (including histidines on
position 59 and 90 of Hcrt56–68 and Hcrt87–99, respectively), thereby
increasing homology between H1N1-HA275–287 and the Hcrt peptides.
Additionally, the histidine residue on position 59 of the first Hcrt
peptide (Hcrt56–68) was replaced by an oxo-histidine or alanine residue
rendering the two peptides more homologous to H1N1-HA275–287.
Soluble complexes of HLA-DQ6 containing the peptides H1N1-
HA275–287, Hcrt56–68 and Hcrt87–99 were produced essentially as de-
scribed previously for HLA-DQ2 (Henderson et al., 2007; Petersen et al.,
2014). Briefly, the αβ-heterodimer of the HLA-DQ6 extracellular do-
main was expressed in Hi5 insect cells, with each peptide linked to the
N-terminus of the HLA-DQ6 β-chain. The C-termini of the constructs
contained an enterokinase cleavable Fos/Jun zippers, and, at the C
terminus of the β-chain, a BirA biotinylation sequence followed by a
His10-Tag. The complexes were purified via diafiltration, metal affinity,
size exclusion and ion exchange chromatography. For crystallisation
experiments the Fos/Jun zippers were removed by enterokinase clea-
vage and ion exchange chromatography.
2.4. Crystallisation, data collection, structure determination and refinement
Peptide-HLA-DQ6 complexes were crystallised at 20 °C via the
hanging drop vapor diffusion method using equal volumes of mother
liquor and protein solution at 10mg/mL in a buffer containing 10mM
Tris (pH 8) and 150mM NaCl. HLA-DQ6-Hcrt56–68 and HLA-DQ6-
Hcrt87–99 were crystallised with mother liquor containing 16–20%
PEG4000, 0.1M NaOAc pH 4.5–5.0, and HLA-DQ6- HA275–287 was
crystallised with 23% PEG4000, 0.2M NaI, 0.1M HEPES pH 7. Prior to
data collection the crystals were cryoprotected in mother liquor sup-
plemented with 20% glycerol, or 20% ethylene glycol in the case of
HLA-DQ6- Hcrt87–99, and flash frozen in liquid N2. X-ray diffraction
data was collected at the mx2 beamline of the Australian Synchrotron
using a ADSC Q315r detector and data processing was carried out with
XDS (Kabsch, 2010) and Scala (Evans, 2006). The crystal structures
were solved by molecular replacement in Phaser (Mccoy et al., 2007)
using a published HLA-DQ6 structure (PDB code 1UVQ) as search
model. The structural models were refined by iterative rounds of model
building in Coot (Emsley et al., 2010) and restrained refinement in
Phenix (Adams et al., 2010). For further details on data collection and
refinement statistics, see Table 1.
2.5. Peripheral blood mononuclear cell (PBMC) isolation
Blood was drawn from all patients and healthy controls. PBMCs
were extracted using Ficoll-Paque (GE Healthcare, Chicago, USA) gra-
dient reagent. The first experiments were performed on fresh PBMCs,
but in the remainder the isolated PBMCs were subsequently frozen in
10% dimethyl sulfoxide (DMSO; Sigma Aldrich, Saint Louis, USA) in
fetal calf serum (FCS; Sigma Aldrich, Saint Louis, USA). These samples
were stored until use in liquid nitrogen vessels.
2.6. Antigen-specific T cell lines
After isolating or thawing of PBMCs of narcolepsy type 1 patients
and healthy controls, 1× 106 cells were put into culture in Iscove's
Modified Dulbecco's Medium (IMDM; Lonza, Basel, Switzerland) sup-
plemented with L-glutamine (Thermo Fisher, Waltham, USA), 10%
(pooled) human serum (NHS) and a mixture of the H1N1-HA275–287,
Hcrt56–68 and Hcrt87–99 peptides. After every 5 days r-interleukin 2
(20 U/mL final concentration; rIL-2; Novartis, Basel, Switzerland) and
interleukin 15 (10 ng/mL final concentration, IL-15; R&D, Minneapolis,
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USA) were added to each culture (Kooy-Winkelaar and Koning, 2015).
2.7. Peptide-specific T cell clone generation
Peptide-specific T cell clones (TCCs) were generated from T cell
lines specific for H1N1-HA275–287 from 3 narcolepsy patients by limiting
dilution in culture medium containing 106 irradiated feeder cells/mL,
20 U/mL rIL-2, 10 ng/mL IL-15 and 1 μg/mL PHA (“feeder mix”; Remel,
Lenexa, USA). The cells were stimulated with 20 U/mL rIL-2 and 10 ng/
mL in 10% human serum/IMDM after 5 days. After 10 days, growing
wells were transferred to 24-well plates and cultured in feeder mix until
a confluent layer of cells was formed. For the T cell lines of 9 narcolepsy
patients, streptavidin-PE-HLA-DQ6- H1N1-HA275–287 and streptavidin-
PE-HLA-DQ6-Hcrt56–68 and -Hcrt87–99 tetramers were used to directly
stain HLA-H1N1-HA275–287-, -Hcrt56–68- and -Hcrt87–99 -specific T cells.
Tetramers were produced essentially as described (Ooi et al., 2017).
These tetramer-positive CD4+ T cells were sorted by flow cytometry on
a FACS-Aria III instrument (BD Biosciences) and expanded as described
above. Clones were subsequently generated from the identified H1N1-
HA275–287-specific and/or Hcrt56–68- or Hcrt87–99-specific T cells, as
described previously (Kooy-Winkelaar and Koning, 2015). All T cell
lines used for TCC generation were derived from frozen narcolepsy
patient samples.
2.8. Flow cytometry
Peptide-specific T cell lines generated from one patient were in-
cubated for 30min with 11 antibodies for surface staining and subse-
quently acquired on a LSRII instrument (BD Biosciences).
Fluorochrome-labelled antibodies directed against CD3 (clone UCHT1),
CD4 (clone SK3), CD5 (clone L17F12), CD7 (clone M-T701), CD14
(clone MφP9), CD27 (clone M-T271), CD28 (clone CD28.2), CD45RA
(clone L48) and IgG1 (clone MOPC-21) were from BD Biosciences (San
Jose, California, USA), anti-CD8 (clone 3B5) was from Invitrogen
(Bleiswijk, the Netherlands) and anti-CD45 (clone HI30) from
eBioscience (San Diego, California, USA). Results were analysed using
FlowJo V.10 software (Schmitz et al., 2016).
2.9. T cell proliferation assay and assays for assessing HLA-DQ6 restriction
Proliferation assays were performed on T cell lines and TCCs in
triplicate in 150 μl IMDM supplemented with 10% human serum in 96-
well, flat-bottom plates (Corning Life Sciences, Tewksbury, USA) using
1×104 T cells stimulated with 1×105 irradiated HLA-DQA1*01:02/
DQB1*06:02 (HLA-DQ6)-matched allogeneic PBMCs (3000 RAD) in the
presence or absence of either H1N1-HA275–287 or Hcrt56–68 and
Hcrt87–99 (10 μg/mL). In HLA-restriction experiments, the HLA-
DQA1*01:02/DQB1*06:02-matched allogeneic PBMCs were replaced
by PBMCs expressing either HLA-DQA1*03:01/DQB1*03:02 (HLA-DQ8;
no association with narcolepsy), HLA-DQA1*01:02/DQB1*06:03 (less
frequently found in narcolepsy compared to healthy controls (Tafti
et al., 2014)) or a mix of HLA-DQA1*01:02/DQB1*06:02 and HLA-
DQA1*01:02/DQB1*06:03. Triplicate wells containing 104 T cells sup-
plemented with 20 U/mL rIL-2 and 10 ng/mL IL-15 functioned as a
positive control. After 48 h at 37 °C, cultures were pulsed with 10 μCi/
mL of 3H-thymidine and harvested 18 h later. Proliferation was mea-
sured using a MicroBeta Microplate Counter (PerkinElmer, Waltham,
MA, USA). A positive response was defined as a stimulation index (SI)
of 3 (defined as the mean count in the wells with peptides divided by
the mean count in the wells without peptide) (Kooy-Winkelaar and
Koning, 2015). Additionally, to confirm HLA restriction of the T cell
lines, blocking experiments were performed in which either anti-HLA-
class I (W6/32), anti-HLA-DP (B7/21), anti-HLA-DQ (SPV-L3) or anti-
HLA-DR (B8.12.2) monoclonal antibodies (mAbs; locally produced)
were added to the initial assay.
Table 1
Data collection and refinement statistics.
Wavelength HLA-DQ6-Hcrt56–68 HLA-DQ6-Hcrt87–99 HLA-DQ6-H1N1-HA275–287
Resolution range 34.52–2.0 (2.071–2.0) 39.56–1.936 (2.005–1.936) 40.11–1.7 (1.761–1.7)
Space group C 1 2 1 P 2 21 21 P 21 21 21
Unit cell 163.063 72.404 99.277 72.538 99.549148.372 55.764 89.58115.484
90,113.763 90 90 90 90 90 90 90
Total reflections 137,291 (13803) 160,661 (15461) 126,644 (12583)
Unique reflections 70,012 (6989) 80,479 (7782) 64,298 (6352)
Multiplicity 2.0 (2.0) 2.0 (2.0) 2.0 (2.0)
Completeness (%) 97.65 (97.90) 99.54 (97.12) 99.84 (99.95)
Mean I/sigma(I) 7.34 (1.86) 9.85 (2.37) 10.47 (2.31)
Wilson B-factor 22.44 23.29 17.15
R-merge 0.06104 (0.3654) 0.03506 (0.2447) 0.04976 (0.3822)
CC1/2 0.995 (0.835) 0.999 (0.948) 0.994 (0.685)
CC* 0.999 (0.954) 1 (0.987) 0.999 (0.902)
R-work 0.1755 (0.2524) 0.1882 (0.2668) 0.1705 (0.2377)
R-free 0.1980 (0.2795) 0.2157 (0.2819) 0.1972 (0.2680)
Number of non‑hydrogen atoms 6888 6696 3720
Macromolecules 6044 5990 3083
Ligands 76 90 95
Solvent 768 616 542
Protein residues 751 745 384
RMS (bonds) 0.008 0.009 0.009
RMS (angles) 1.17 1.25 1.46
Ramachandran favored (%) 98.09 97.65 97.61
Ramachandran allowed (%) 1.91 2.35 2.39
Ramachandran outliers (%) 0.00 0.00 0.00
Rotamer outliers (%) 0.60 1.21 0.59
Clashscore 5.44 5.58 4.36
Average B-factor 43.49 45.13 26.10
Macromolecules 43.27 44.94 22.61
Ligands 69.59 77.29 77.67
Solvent 42.63 42.29 36.94
HA=hemagglutinin; Hcrt= hypocretin.
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2.10. T cell receptor (TCR) sequencing
TRAV, TRBV and CDR3 gene segment sequences of H1N1-HA275–287-
specific TCCs were amplified using PCR and a set of specifically de-
signed primers. PCR products rendered in this way were cloned into a
Promega pGEM-T Easy vector and subsequently sequenced. The TRAV
and TRBV gene usage and CDR3 sequences for all generated clones were
determined using IMGT/V-QUEST (Brochet et al., 2008).
2.11. Statistical analysis
Differences at baseline in participant characteristics were calculated
with Student's t-tests and Pearson's chi-square test. Pearson's chi-square
test was also used for comparing T cell proliferation in narcolepsy pa-
tients as compared to healthy controls. Differences between conditions
in the HLA blocking experiments were calculated by one-way ANOVA
with a Bonferroni post hoc analysis. Differences between P-values
below 0.05 were deemed significant. Bonferroni corrections were exe-
cuted when needed. All analyses were conducted using the IBM SPSS
Statistics 23 software package.
3. Results
3.1. Patient characteristics
We included 81 narcolepsy type 1 patients and 19 healthy controls.
Patient characteristics are shown in Table 2. Notably, all narcolepsy
type 1 patients except one were HLA-DQA1*01:02/DQB1*06:02 (HLA-
DQ6) positive. Thirty-four patients had undergone a lumbar puncture
for Hcrt-1 measurement; all had Hcrt-1 values in the cerebrospinal fluid
that were below the cut-off value of 110 pg/mL based on the ICSD-3
criteria for narcolepsy type 1. Narcolepsy type 1 patients were younger
than healthy controls, but the distribution of males and females was
comparable between the two groups.
3.2. H1N1-HA275–287, Hcrt56–68 and Hcrt87–99 presented by HLA-DQ6
show structural homology
Based on earlier described peptides of H1N1-HA and hypocretin that
are able to bind HLA-DQ6 (De La Herran-Arita et al., 2013, 2014), we
investigated the possibility of molecular mimicry between H1N1-HA
and Hcrt peptides in the context of HLA-DQ6 presentation. We crys-
tallised and determined the crystal structures of H1N1-HA275–287,
Hcrt56–68 and Hcrt87–99 presented by HLA-DQ6 at resolutions of 1.7 Å,
2.0 Å and 1.95 Å, respectively (Fig. 1). Alignment of the structures re-
vealed that the two Hcrt peptide - HLA-DQ6 complexes, HLA-DQ6-
Hcrt56–68 and HLA-DQ6-Hcrt87–99, were nearly indistinguishable in
terms of peptide backbone positioning (Cα rmsd<0.1 Å), peptide
sidechain conformations and HLA substructure surrounding the pep-
tide. Compared to the two Hcrt complexes, the H1N1-HA275–287 peptide
was bound to HLA-DQ6 in the expected homologous register and with
overall similar backbone positioning (Cα rmsd<0.35 Å) and sidechain
conformations. Within the 9-mer core of the bound peptides, the most
notable differences were observed in the exposed positions p2 and p8 of
the peptides (p2-histidine and p8-threonine in the Hcrt complexes, and
p2-alanine and p8-isoleucine in the H1N1-HA complex). In addition to
the differences in peptide sidechains, we observed a difference in the β-
chain helix, which was positioned closer to the peptide in the H1N1-HA
complex when compared to the two Hcrt complexes. This homology
prompted us to determine whether this could also lead to T cell cross-
reactivity to the H1N1-HA and hypocretin peptides in functional ex-
periments.
3.3. HLA-DQ6-H1N1-HA275–287-specific CD4+ T cells are readily
detectable in narcolepsy type 1 patients and healthy controls, but do not
cross-react with HLA-DQ6-Hcrt56–68 or -Hcrt87–99
T cell lines were generated from PBMCs of narcolepsy type 1 pa-
tients and healthy controls by co-culture with a pool of the H1N1-
HA275–287, Hcrt56–68 and Hcrt87–99 peptides for 5 days followed by ex-
pansion in culture medium containing IL-2 and IL-15. Subsequently, the
specificity of these T cell lines against the H1N1-HA275–287 peptide was
determined by co-culture of the T cell lines with irradiated HLA-DQ6
positive allogeneic PBMCs in the presence or absence of the H1N1-
HA275–287 peptide. Specific proliferation was measured by determining
the incorporation of 3H-thymidine after three days of culture.
Proliferation was defined as a stimulation index equal or higher to 3. All
T cell lines proliferated in the positive control condition which re-
inforced our earlier conclusion based on visual assessing T cell lines that
they were in good condition. In 28.4% (23/81) of narcolepsy type 1
patients and 15.8% (3/19) of healthy controls, an H1N1-HA275–287-
specific T cell proliferative response was observed (Fig. 2). To assess the
specificity of the T cell lines against the Hcrt peptides, they were also
stimulated with the Hcrt56–68 and Hcrt87–99 peptides. No reactivity to
Hcrt56–68 or Hcrt87–99 was observed in T cell lines of either narcolepsy
type 1 patients or controls (Fig. 2), indicating the absence of cross-re-
activity of H1N1-HA275–287-specific T cells with Hcrt56–68 and Hcrt87–99
in the context of HLA-DQ6. FACS analysis was performed on 13 HLA-
DQ6-H1N1-HA275–287-specific T cell lines. Analyses revealed a dom-
inance of CD4+ T cells in these T cell lines (Fig. 3).
3.4. T cell reactivity to H1N1-HA275–287 is HLA-DQ6-restricted
T cell clones (TCCs) were generated from the H1N1-HA275–287-re-
active T cell lines of 12 narcolepsy type 1 patients by either limiting
dilution (in T cell lines of 3 narcolepsy type 1 patients) or isolation
using streptavidin-PE-HLA-DQ6- H1N1-HA275–287 tetramers (in T cell
lines of 9 narcolepsy type 1 patients) and tested for reactivity against
H1N1-HA275–287. In TCCs generated from all H1N1-HA275–287-specific
CD4+ T cell lines, H1N1-HA275–287-specific clonal T cell responses
were found (Table 3).
To assess HLA-DQ6 restriction, T cell proliferation experiments were
performed with irradiated allogeneic PBMCs of different haplotypes:
HLA-DQA1*01:02/DQB1*06:03, HLA-DQA1*03:01/DQB1*03:02 (HLA-
DQ8) or a mix of HLA-DQA1*01:02/DQB1*06:02 and HLA-
DQA1*01:02/DQB1*06:03 next to those expressing HLA-DQA1*01:02/
DQB1*06:02. T cell proliferation was only observed in the presence of
HLA-DQ6-expressing PBMCs and the H1N1-HA275–287 peptide.
Furthermore, when T cell proliferation experiments were performed
with irradiated allogeneic PBMCs expressing HLA-DQ6, an anti-HLA-
DQ mAb was able to block T cell proliferation of the generated TCCs. An
anti-HLA-class I mAb blocked T cell proliferation considerably less ef-
fectively, whereas anti-HLA-DR and –DP mAbs did not affect T cell
proliferation (Fig. 4A-B). These experiments confirm that the detected
H1N1-HA275–287-specific CD4+ T cell proliferation is HLA-DQ6-re-
stricted.
Table 2
Characteristics of study participants. Data indicate mean ± standard devia-
tion. P-values result from Student's t-tests for the continuous variables and
Pearson's chi-square tests for dichotomous variables.
Narcolepsy type
1
Healthy
controls
p-Value
N 81 19
Age (years) 31.6 ± 19.2 55.0 ± 8.4 <0.001
Males (%) 39 (48.1%) 9 (47.4%) 0.951
HLA-DQ6 + 80/81 19/19 0.626
Hypocretin-1 < 110 pg/mL 34/34 Not available Not applicable
H1N1 vaccination (%) 15/47 (32%) Not available Not applicable
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3.5. The HLA-DQ6-H1N1-HA275–287-specific T cell receptor repertoire in
narcolepsy type 1 patients and healthy controls shows no biased expression
Recent reports describe a bias in TCR sequences for recognition of
peptide-HLA complexes in CD4+ T cell mediated diseases (Qiao et al.,
2014; Petersen et al., 2014). Since we were not able to show significant
differences between percentages of narcolepsy type 1 patients and
controls with HLA-DQ6-H1N1-HA275–287-specific T cells, we searched
for differences in the T cell repertoire used by narcolepsy type 1 pa-
tients and controls to mount immune responses to this antigen. TCRs
expressed by 20 H1N1-HA275–287-specific TCCs from 4 narcolepsy type
1 patients and 4 H1N1-HA275–287-specific TCCs from 2 healthy controls
were sequenced (Table 4). 18 TCR sequences were identified in TCCs of
narcolepsy type 1 patients; 4 different TCR sequences in TCCs of
healthy controls. There was expansion of some clones within a given
patient, but these likely arose during the culturing process, with some T
cell clones responding better to peptide hence expanding at a greater
rate than others subsequently skewing the representative pool. Never-
theless, although only a small sample size was interrogated, no evi-
dence for a biased TRAV, TRBV or CDR3 sequence motif was observed
across unrelated individuals with narcolepsy type 1 or in healthy con-
trols.
4. Discussion
HLA-DQ6-H1N1-HA peptide-specific CD4+ T cell responses were
readily detected in both narcolepsy type 1 patients and healthy con-
trols, with a higher proportion in the narcolepsy type 1 group. We did
not detect HLA-DQ6-Hcrt peptide-specific T cell responses. Our ex-
periments do not support the hypothesis that these Hcrt peptides are
implicated in cross-reactivity leading to Hcrt-producing neuronal de-
struction and, thereby, to narcolepsy type 1.
The HLA-DQ6-H1N1-HA peptide-specific TCCs did show some, but
Fig. 1. HLA-DQ6 presenting H1N1-HA275–287, Hcrt56–68 and Hcrt87–99 peptides show structural homology. A. H1N1-HA275–287 peptide. B. Hcrt56–68 peptide. C.
Hcrt87–99 peptide. D. Overlay A., B. and C.
HA=hemagglutinin; Hcrt= hypocretin.
Fig. 2. Overview of T cell responses to H1N1-HA275–287, Hcrt56–68 and Hcrt87–99
for narcolepsy type 1 patients (red) and healthy controls (green). The P-value
results from a Mann-Whitney U test. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this
article.)
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no extensive clustering of T cell receptor sequences in narcolepsy type 1
patients. Larger studies would be required to determine if the H1N1-
specific TCR repertoire in NT1 patients differs from controls.
Our findings add to those of others in the field who did show an-
tibody-mediated reactivity to H1N1-HA in narcolepsy type 1 patients.
Several groups found H1N1-HA specific antibodies in narcolepsy type 1
patients (Lind et al., 2017; Lind et al., 2014), but H1N1-HA specific T
cells have not been described. The lack of reactivity to Hcrt peptides
was reported in studies focusing on autoantibodies (Black et al., 2005)
and CD4+ T cells (Ramberger et al., 2017; Kornum et al., 2017). HLA-
DR-restricted Hcrt-specific T cell responses have recently been de-
scribed (Latorre et al., 2018), but that study does not explain the strong
link with HLA-DQ6. Interestingly, one other study (Ramberger et al.,
2017) reported reactivity to Hcrt-peptide pools in a small minority of
narcolepsy type 1 patients, although the peptides used differed from the
ones in the current study.
Moreover, in our current study we focused on H1N1-HA and Hcrt
peptides that display sequence homology, which does not rule out that
other H1N1 peptides are involved. Another possibility is that the key
differences between the peptides, a histidine residue at position 59 and
90 of the Hcrt56–68 and Hcrt87–99 peptides, respectively, as compared
with an alanine residue in the corresponding position in the H1N1-
HA275–287 peptide, may prevent cross-reactive responses. We therefore
also tested substitution variants of the Hcrt-peptides in which the his-
tidine residues were replaced by an alanine, but we observed no cross-
reactivity to these peptides as well, making it unlikely that post-
translational modification of Hcrt-peptides underlies cross-reactivity
(results not shown). In future studies we will therefore be testing T cell
responses to peptide pools representing the H1N1 proteome and pre-
prohypocretin.
One of the limitations in our study is that we have not been able to
distinguish between narcolepsy type 1 patients and healthy controls
that have actually encountered the H1N1 influenza virus and those who
have not. We could therefore not be sure whether different exposure to
the virus explains the lack of differences in H1N1-HA peptide-specific T
cell responses between narcolepsy patients and healthy controls.
However, T cell mediated cross-protective immunity generated by
previous H1N1 infections was found to be common in the population
(Miller et al., 2010).
Fig. 3. H1N1-HA275–287-specific T cell lines are predominantly CD4+. These fluorescence-activated cell sorting (FACS) plots show the gating strategy of two T cell
lines in different patients (A-C and D-F). Living single cells are selected in the FSC-SSC plot (A and D). In the next plot CD3+ cells are selected (B and E), which show
a high percentage of CD4+ cells in the last plot (C and F).
Table 3
H1N1-HA275–287-specificity of the generated T cell clones (TCCs). All subjects
are narcolepsy type 1 patients.
Subject number H1N1 vaccination TCCs tested H1N1-HA275–287-specific
TCCs
19a Yes 50 1
24 No 25 25
25 No 11 11
26 No 11 11
27a Yes 109 19
29 Yes 5 5
32 Unknown 14 14
35 Unknown 12 12
38 Yes 11 10
39 Unknown 4 4
47 No 22 22
50a Yes 130 23
a TCC generation using limiting dilution instead of tetramer sorting.
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Another limitation in our study is that we are performing our ex-
periments in blood, while the actual destruction of Hcrt-producing neu-
rons is taking place at the other side of the blood-brain barrier. It was
recently described that T cell composition in cerebrospinal fluid differed
between narcolepsy type 1 patients and healthy controls (Moresco et al.,
2018). Repeating our experiments in cerebrospinal fluid would therefore
be a better environment to test for cross-reactive T cells.
Additionally, detecting proliferation of a small immune subset that
could have driven the destruction of the approximately 80,000 Hcrt-
producing neurons (Thannickal et al., 2000) in a vast number of non-
proliferating immune cells is technically difficult. The procedure used
for peptide-specific TCC generation was also used in previous studies
for the isolation of HLA-DQ-restricted gluten-specific T cell clones from
patients with celiac disease in which we have determined the affinity of
such T cells for the cognate HLA-DQ-gluten complexes. We observed
that in cell-free assays the affinity values for some of these HLA-DQ-
gluten specific TCRs were comparable with affinity values observed for
microbial or non-self TCR–pMHC-II interactions, while others exhibited
affinity values in line with those of low-affinity autoreactive
TCR–pMHC complexes (Petersen et al., 2014). In cellular assays similar
substantial differences were observed (Broughton et al., 2012). There-
fore, this indicates that our method allows the identification of both
high- and low-affinity T cell clones. However, we cannot exclude the
possibility that with our technique we missed the detection of very low
frequency T cells. The T cell library method that was performed in a
recent publication on T cell reactivity to Hcrt (Latorre et al., 2018)
would be an interesting technique to screen for these low frequency
clones. Other novel approaches, such as mass cytometry, to address this
rare immune subset problem are emerging with techniques that can
isolate disease-specific immune subsets with unprecedented detail (Van
Unen et al., 2017). Repeating our experiments with only those subsets
that are specific for narcolepsy type 1, would significantly increase the
odds of identifying rare cross-reactive immune cells in narcolepsy type
1 patients should they exist.
Fig. 4. A. A H1N1-HA275–287 dose-dependent T cell
response in a narcolepsy type 1 patient T cell clone
(patient number 50, TCC 87) is found only in
proliferation experiments performed with irra-
diated PBMCs that are HLA-DQA1*01:02/
DQB1*06:02 (HLA-DQ6)-positive. Experiments
were performed in triplicate wells. Significant
differences relative to proliferation experiments
with irradiated HLA-DQ8 (HLA-DQA1*03:01/
DQB1*03:02)-positive PBMCs. B. Anti-HLA-DQ
mAb blocks T cell proliferation of the generated
TCCs. An anti-HLA-class I mAb blocked T cell
proliferation considerably less effectively, whereas
anti-HLA-DR and –DP mAbs did not affect T cell
proliferation.
* p < .05, ** p < .01, *** p < .001;
mAb=monoclonal antibody; PBMCs= peripheral
blood mononuclear cells; TCC=T cell clone.
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5. Conclusions
We identified HLA-DQ6-restricted H1N1-HA peptide-specific T cell
responses in a subset of narcolepsy type 1 patients and healthy controls.
We did not find HLA-DQ6-H1N1-HA peptide-specific T cells cross-re-
active to Hcrt-2 peptides. These results indicate that it is unlikely that
cross-reactivity between H1N1-HA and Hcrt-2 peptides presented by
HLA-DQ6 is involved in the development of narcolepsy.
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